Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 17/20 | 0.63 |
| ▸ | DRD2 | P14416 | 15/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30378970 | 1.00 | DRD4 (0.63) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL30379884 | 0.92 | BRD4 (0.64) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL26088857 | 0.92 | BRD4 (0.64) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL26088673 | 0.90 | DRD4 (0.65) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL30379414 | 0.90 | DRD4 (0.65) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL26092155 | 0.89 | DRD4 (0.61) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL30910047 | 0.89 | DRD4 (0.61) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL30378997 | 0.89 | DRD2 (0.56) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL26091831 | 0.89 | DRD2 (0.56) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL30379412 | 0.88 | DRD4 (0.60) | DRD4DRD2MEN1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023068755-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 사피엔스바이오 | 2023-04-27 | — | — | WO | claimed |
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAPIENSBIO INC. (KR) | 2025-01-02 | — | — | US | disclosed |
| EP-4421070-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sapiensbio Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-118119612-A | Novel compounds and pharmaceutical compositions comprising the same | 萨皮恩斯生物有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023068755-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 사피엔스바이오 | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | RHOA, ACTR2, MFAP1 | DRD4 3728/4885DRD2 4068/4885MEN1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.